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AbstrACt
Introduction Depression is the leading cause of life years 
lost due to disability. Appropriate prevention has the potential 
to reduce the incidence of new cases of depression, however, 
traditional prevention approaches face significant scalability 
issues. Prevention programmes delivered by via smartphone 
applications provide a potential solution. The workplace is an 
ideal setting to roll out this form of intervention, particularly 
among industries that are unlikely to access traditional 
health initiatives and whose workplace characteristics 
create accessibility and portability issues. The study aims 
to evaluate the effectiveness of a smartphone application 
designed to prevent depression and improve well-being. 
The effectiveness of the app as a universal, selective and 
indicated prevention tool will also be evaluated.
Methods and analysis A multicentre randomised controlled 
trial, to determine the effectiveness of the intervention 
compared with an active mood monitoring control in 
reducing depressive symptoms (primary outcome) and 
the prevalence of depression at 3 months, with secondary 
outcomes assessing well-being and work performance. 
Employees from a range of industries will be invited to 
participate. Participants with likely current depression at 
baseline will be excluded. Following baseline assessment, 
participants, blinded to their allocation, will be randomised 
to receive one of two versions of the application: headgear 
(a 30-day mental health intervention) or a control application 
(mood monitoring for 30 days). Both versions of the app 
contain a risk calculator to provide a measure of future 
risk. Analyses will be conducted within an intention-to-treat 
framework using mixed modelling, with additional analyses 
conducted to compare the moderating effect of baseline risk 
level and depression symptom severity on the intervention’s 
effectiveness.
Ethics and dissemination The current trial has received 
ethics approval from the University of New South Wales 
Human Research Ethics Committee (HC17021). Study results 
will be disseminated through peer-reviewed journals and 
conferences.
trial registration number ACTRN12617000548336; 
Results.
IntroduCtIon 
Mental health (MH) conditions are the 
leading cause of long-term disability in most 
middle-income and high-income countries.1 2 
This is mainly due to the impact of anxiety and 
mood disorders in individuals of working age, 
which have pooled 12-month prevalence rates 
of 10.6% and 4.1%, respectively.3–5 To date, 
most of the effort to reduce the burden of 
these disorders has been targeted at ensuring 
treatment is given to those with manifest 
disorders. Although effective treatments are 
available, cost-effectiveness models suggest 
that even in the unlikely event of optimal 
treatment being delivered to all cases, only 
35%–50% of the overall burden of common 
mental disorders would be alleviated.6 As a 
result, effective preventative interventions, 
that intervene prior to onset of full-diagnostic 
disorder, must be a key component of the 
public health response to this problem.7 8 
There is increasing evidence that preven-
tion of mental disorders is possible, either via 
programmes based on reducing established, 
modifiable risk factors (including transdi-
agnostic factors) or by training to enhance 
resilience.9 However, the cost associated with 
delivering most face-to-face psychological 
prevention programmes has made large scale 
roll-outs unfeasible.10 Consequently, most 
trials of MH prevention programmes have 
either used youth samples, where teachers 
and classrooms can be used to deliver face-
to-face interventions,11–13 or adult popula-
tions with subclinical symptom levels14 15 or 
other comorbid conditions placing them 
strengths and limitations of this study
 ► Large multisite trial (over 2000 participants), making 
this the largest ever depression prevention trial.
 ► Intention-to-treat analysis and randomised con-
trolled trial gold standard design, with active control.
 ► Ability to compare the relative efficacy of universal, 
selective and indicated prevention approaches.
 ► The use of a novel app-based intervention in the 
workplace.
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at substantially increased risk.16 As a result, it remains 
unclear which, if any, preventive interventions are effec-
tive in a more generalised population. A recent systematic 
review and meta-analysis suggested that there is emerging 
evidence that several common psychotherapeutic tech-
niques, such as cognitive– behavioural therapy (CBT), 
may be effective in preventing common mental disorders 
in non-selected general populations.17 To date though, 
large-scale studies are lacking, and the relative utility 
of some of the less complex (and cheaper) techniques, 
such as behavioural activation (BA), remains unknown.18 
There is also a paucity of evidence indicating which 
populations might be the prime targets for prevention 
efforts. Prevention efforts are generally categorised into 
three groups: universal, where a prevention initiative is 
directed at an entire population; selective, where efforts 
are focused on those at high risk and indicated, where 
prevention is directed at those with emerging symptoms.
As the workplace is a dominant setting in the lives of 
many adults, it is increasingly being recognised as a prime 
location for MH prevention interventions,19 especially as 
44% of working Australians report workplace issues as a 
source of stress.20 While workplace stress is not localised 
to any particular industry, the issue appears to be more 
pertinent in male-dominated industries (MDIs) where 
employees have been found to have elevated rates of 
anxiety and mood disorders compared with other indus-
tries.21 22 MDIs highlight the interplay between work-
place-related factors (highly mobile, remote or isolated, 
irregular workloads21) and the sociodemographic features 
of the worker (lower health literacy and lower rates of 
help seeking23 24) in contributing to these elevated rates. 
These industries also highlight the current limitations of 
conventional prevention programmes, which are neither 
accessible nor portable to all industries and represent a 
traditionally underserviced group. Recent rapid growth 
in the areas of eHealth and mHealth (healthcare prac-
tices supported by internet or mobile phone technolo-
gies) represent new frontiers for delivering and targeting 
MH interventions.25–29 These developments provide a 
potential solution to the barriers involved in delivering 
individually tailored prevention measures across a wide 
population in a practical, anonymous (thereby counter-
acting MH stigma) and cost-effective manner. Indeed, 
the ubiquity of personally owned devices increases the 
feasibility of mobile MH care interventions.30 While the 
effectiveness of internet and smartphone applications as 
a treatment for common mental disorders has been evalu-
ated extensively31—and the workplace as a specific setting 
for these interventions—to19 date there have been rela-
tively few trials examining the effectiveness of these types 
of intervention in preventing mental disorders.32
The proposed headgear trial aims to evaluate the effec-
tiveness of a new smartphone app designed to prevent 
depression in Australian workers. As well as assessing the 
overall effectiveness of the intervention, the study also 
aims to compare the relative efficacy of universal, selec-
tive and indicated prevention approaches as defined 
through the identification of relevant subgroups of the 
sample recruited.
MEthods
design
The above aims will be achieved in a multicentre 
randomised controlled trial, with two parallel arms. Two 
smartphone app-based interventions will be compared: 
a new intervention for primary prevention of common 
mental disorders (headgear) and a specially developed 
active control. Assessments will occur at baseline, postin-
tervention (5 weeks) and 3-month follow-up. The study 
is registered with the Australian New Zealand Clinical 
Trials Registry (ACTRN12617000548336). Consent will 
be obtained electronically from all participants and any 
identifiable data encrypted. The study will be conducted 
in accordance with the Declaration of Helsinki33 and is 
compliant with the Standard Protocol Items for Reporting 
in Trials34 and Consolidated Standards of Reporting 
Trials35 guidelines. 
setting and participants
The study will recruit Australians who are currently 
employed and will sample more selectively from a range 
of MDIs. A MDI is defined as one in which ≥70% of 
workers are male.36 In Australia, these industries include 
agriculture/forestry/fishing, utility services (electricity, 
gas, water and waste), wholesale trade, manufacturing, 
transport/postal/warehousing, mining and construc-
tion.36 Emergency services and defence also fit this defi-
nition, but were not considered unique industries by the 
Australian Bureau of Statistics (ABS), for this study they 
were considered as such.
A number of industry partner organisations will provide 
the trial sites for this study. These partners comprise a 
range of industries including transport, postal, mining, 
construction, emergency services and utility services and 
have sites across Australia. Each organisation has offered 
access to specific sites, or to their entire workforce.
We will aim to recruit a total sample of at least 2100 
employed adults across Australia (see sample size calcula-
tion below). Industry partner organisations will promote 
the study via their respective health and well-being offi-
cers, chaplaincy and peer-support committees, along with 
email and newsletter advertisements. Social media adver-
tising targeted at employed people will also be used to 
recruit beyond the partner organisations using a similar 
approach to previous studies.37 The study will also be 
promoted via members of the research team presenting 
at partner worksites. Both men and women will be 
recruited, though it is anticipated that more than half of 
the sample will be men due to the focus on MDIs.
Eligibility criteria
Initial eligibility criteria are: having a valid telephone 
number, ownership of an Apple-operating/Android-op-
erating smartphone, currently employed and living in 
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Australia. Participants will be excluded if they do not have 
reliable internet access at home or at work, or cannot 
read English. As this trial is focused on the prevention of 
depression, participants will also be excluded from this 
trial (although still permitted to use the app) if they have 
substantial levels of depression symptoms at baseline, 
as indicated by a score above 14 or meeting the major 
depressive disorder (MDD) diagnosis algorithm using the 
Patient Health Questionnaire-9 item (PHQ-9).
Interventions
Active intervention: headgear
The intervention condition, headgear, is a smartphone 
application-based intervention centred on BA and mind-
fulness. BA is a therapy that reconnects people to an envi-
ronment of positive reinforcement using value-driven 
goal setting,38 39 and has been shown to perform as well 
as full CBT18 for the treatment of depression. Although 
primarily used as a treatment for clinically depressed 
clients, a recent metanalytic review has found a signifi-
cant and moderately sized effect of BA interventions on 
well-being (a risk factor for depression40), regardless of 
depression status.41 The other component, mindfulness 
is both a process (meditation) and an outcome (mindful 
awareness),42 shown to have diagnosis independent 
effects in reducing depression, anxiety43 and stress levels 
(a risk factor for depression44) in healthy individuals.45
The main therapeutic component of the headgear app 
takes the form of a 30-day intervention in which users 
complete one ‘challenge’ daily (5–10 min per day). These 
‘challenges’ feature a variety of evidence-based therapeutic 
techniques and formats. The modules are structured, so a 
participant might be presented with a psychoeducational 
video (eg, on BA, mindfulness, coping skills or resilience) 
to promote understanding of the concept and/or skill 
on 1 day and then on a following challenge day, partic-
ipants would then practice the skill or apply a concept 
that was previously learnt. Examples of practical exercises 
include mindfulness exercises, value-driven activity plan-
ning, goal setting and coping skill development (problem 
solving, sleep, grounding, alcohol use, assertiveness and 
training in adaptive forms of coping).
For BA, participants will be encouraged to consider 
how increased engagement in activities that are valued 
increases the chance of deriving pleasure and feeling a 
sense of achievement from life. BA’s theoretical underpin-
ning is that a person’s development and maintenance of 
depression is the result of avoidant behaviour as a coping 
mechanism to an environment characterised by low levels 
of positive reinforcement and/or high levels of aversive 
control.46 Thus, by targeting the avoidance behaviours as 
well as broadening the repertoire of behaviours an indi-
vidual engages in, people are more likely to experience 
positive reinforcement in their environment. During 
mindfulness exercises, participants will be taught how 
they can pay more attention to and be more accepting 
of momentary experiences, through standard meditation 
practices such as mindfulness of breath, body scan and 
cognitive defusion. Through such contemplative prac-
tices, the quality of an open, accepting mind is cultivated. 
Such practices are in direct contrast to the maladaptive 
habitual mental processes of depressive disorders which 
have a propensity towards an avoidance of experience and 
an intolerance of negative emotions and cognitions.47 48 
Both BA and mindfulness have been shown to be some of 
the most popular techniques among workers in MDIs.49
Prior to completing the intervention users will complete 
a risk calculator, which will assess and provide participants 
with personalised feedback regarding their risk for future 
MH issues. The risk calculator is an algorithm consisting 
of 20 items developed from the Household, Income and 
Labour Dynamics in Australia Survey (HILDA), and has 
been validated in the Australian adult population.50 The 
HILDA questions and response items were replicated 
from the original items included in the HILDA survey, 
apart from age, which is measured here as a continuous 
measure. Users will receive personalised risk feedback 
immediately after completing the risk calculator. The 
personalised risk feedback involves an interactive icon 
array which displays the calculated numerical risk esti-
mate of developing anxiety and depression within the 
next year, along with a text description.
Other components of the headgear intervention app 
include interactive mood monitoring, a toolbox of skills 
(which is built as the intervention is completed) and 
technical support service helplines. The application has 
been designed to maximise user engagement and adher-
ence, incorporating reward acquisition on completion of 
each daily challenge. The application is the result of an 
iterative development process to allow for optimal func-
tionality and design49 51 Consideration was also given to 
the context and population of working men and women 
in which the trial is taking place. As the majority of the 
population are not currently experiencing distressing 
symptoms of mental ill health, engagement—both gener-
ating motivation to engage and maintaining user engage-
ment over time—is important. To this end steps have been 
taken to promote user motivation and engagement via 
the ‘challenge’ concept in conjunction to other related 
components and technical features aimed to increase the 
app’s appeal.52–54
Control condition: mood monitoring smartphone application
The control condition is a smartphone application that, 
to the user, will have the same name and a virtually iden-
tical look and ‘feel’ as headgear. However, there is no 
skill development and no components of BA or mind-
fulness therapy. To control for the other components 
of the headgear application, the control condition will 
encourage users to use the inbuilt mood monitor daily 
over a 30-day period. To ensure consistent approaches 
between the two applications, participants in the control 
group will receive daily reminders to record their moods 
via the control smartphone application. In conjunction to 
this, participants are able to review their ‘mood history’ in 
a calendar that displays the mood recorded across each 
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day. Participants will also have access to the risk calcu-
lator that will provide participants with individualised risk 
feedback. Controlling for mood monitoring, which is a 
common feature of many commercially available smart-
phone applications, is essential as this alone may bring 
awareness to an individual’s mood and allow them to gain 
greater understanding of the causative behaviours related 
to their mood and associated improvements in mood.
Procedure
All interested employees will be directed to their respec-
tive app store (iTunes or Google Play) directly via adver-
tisements or via a dedicated website (http:// headgear. org. 
au). On downloading the app, participants will provide 
informed consent and then undergo initial screening. 
Participants who meet the inclusion criteria will then be 
randomised to receive either the full headgear app or 
the attention-matched control version of the app. Partici-
pants will be blinded to their allocation.
Those scoring above 14 on the PHQ-9 (or meeting 
MDD diagnosis using the PHQ-9 algorithm)55 at baseline 
will be provided with appropriate referral information 
to health services and crisis lines and will be encouraged 
to seek help from their general practitioner (GP). This 
group will be excluded from this trial. The flow of partici-
pants through the study phases is shown in figure 1.
Patient and public involvement
As this is a prevention study, the participants will be 
employed members of the general public, rather than 
patients. End users were involved in the design of the 
intervention used in the study through participatory 
workshops51 and separate quantitative surveys,49 reported 
on previously. The findings of these studies directly 
Figure 1 Flow of participants through the trial. GP, general practitioner; MDD, major depressive disorder; PHQ-9, Patient 
Health Questionnaire-9 item.
 o
n
 17 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020510 on 13 July 2018. Downloaded from 
5Deady M, et al. BMJ Open 2018;8:e020510. doi:10.1136/bmjopen-2017-020510
Open access
informed the research question and outcome direction 
of this trial. Dissemination of results to participants will 
occur via the project website. All participant burden of 
the trial will be clearly laid out in the information sheet 
prior to consent.
random allocation
Immediately following the completion of the baseline 
questionnaire, the smartphone application will commu-
nicate with a central server (responsible for collecting all 
study data) to assign the participant to either the control 
or treatment condition. The randomisation algorithm 
used by the server will follow a block design with a block 
size of 10, to ensure an equal number of participants are 
assigned to each condition.
Administration of assessments
Assessments will be completed at baseline, postinter-
vention (5 weeks) and 3-month follow-up. Baseline 
assessment includes outcome measures pertaining to 
depression symptomatology PHQ-9,56 well-being (WHO-5 
Well-Being Index (WHO-5)57 58), anxiety symptom-
atology (as measured by the General Anxiety Disorder-2 
item; GAD-259), resilience (Connor-Davidson Resilience 
Scale 10-item; CD-RISC 1060), work performance and 
absenteeism (Health and Work Performance Question-
naire; HPQ61), demographic information and service 
use/management. The application monitors usage 
data including time (amount of time spent in-app) and 
frequency of use, number of log-ins and activity comple-
tion rates. This data will be used to examine programme 
engagement.
Postintervention assessment will occur at 5 weeks post-
baseline, to allow users one extra week to complete the 
30-day programme. To address the possibility that users 
may delete the app during the course of the trial, which 
may hamper follow-up attempts, later follow-ups will occur 
via phone numbers provided, rather than via the applica-
tion. Participants will complete an online questionnaire 
similar to that at baseline (see table 1). This will be repli-
cated at 3 months postbaseline. Participants will receive 
up to three phone-based reminders to complete each 
follow-up. Follow-up measures will be accepted provided 
they are obtained within a 90-day range of the planned 
assessment (up to 90 days after scheduled assessment). 
On completion of each follow-up assessment, participants 
will be entered into a draw for one of four $200 Visa gift 
cards. Strategies to increase response rates followed 
previous published guidance62 including; reducing the 
length of follow-up questionnaires and giving participants 
feedback on their progress while filling out the question-
naire. Similarly, each phone-based reminder incorpo-
rated a reminder of the gift coupon to facilitate increased 
motivation to complete the questionnaires.
Specific measures used in online assessments
The PHQ-9 will be used to measure depression symp-
toms.63 The PHQ-9 is a reliable and valid nine-item 
measure of depression severity over the past 2 weeks in 
clinical and general population samples.56 64–66 Each of 
the nine items of the PHQ-9 is scored as 0 (not at all), 1 
(several days), 2 (more than half the days) or 3 (nearly 
every day). As a screening tool, summing the nine 
items, (score range 0–27 with 0 indicating no depres-
sive symptoms and 27 indicating all symptoms occur-
ring nearly daily). The criterion and construct validity 
of the PHQ-9 have previously been demonstrated, with 
73% sensitivity and 98% specificity (using the depres-
sion diagnostic algorithm) in detecting major depres-
sion compared with clinician-based assessment63 67 and, 
regardless of diagnostic status, typically represents clin-
ically significant depression.63 The measure has demon-
strated excellent internal consistency (Cronbach’s 
α >0.85 in multiple samples) and test–retest reliability 
of 0.84.55
Anxiety will be measured using the GAD-2.59 The GAD-2 
consists of the two core criteria for GAD, which have also 
been shown to be effective screening items for panic, 
social anxiety and post-traumatic stress disorders.59 This 
measure has also been validated in the general popula-
tion.68 Equivalent to the parent scales, the GAD-2 begins 
with the stem question: ‘Over the last 2 weeks, how often 
have you been bothered by the following problems?’ 
Table 1 Assessment measures
Baseline Postintervention 3-month follow-up
Demographics ×
Patient Health Questionnaire-9 item (PHQ-9)55 56 × × ×
General Anxiety Disorder-2 item59 × × ×
WHO-5 Well-Being Index57 58 × × ×
Connor-Davidson Resilience Scale 10-item69 × × ×
Health and Work Performance Questionnaire61 × × ×
Mini-International Neuropsychiatric Interview72* ×
Service utilisation and management items × × ×
Programme feedback ×
*Only for those scoring above 14% and 10% of those scoring below 14 on the PHQ-9 at 3-month follow-up will be contacted via telephone.
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Response options are ‘not at all’, ‘several days’, ‘more 
than half the days’ and ‘nearly every day’, scored as 0, 
1, 2 and 3, respectively (total ranging from 0 to 6). Scale 
scores of ≥3 are suggested as cut-off points between the 
normal range and probable cases of anxiety.59
Resilience will be measured by the CD-RISC, a 10-item 
self-report scale demonstrated to be psychometrically 
sound with high internal consistency (Cronbach’s 
α=0.89), construct validity and test–retest reliability in the 
general population and in clinical settings.60 Total scores 
range from 0 to 40 with higher scores corresponding 
to greater resilience. Validity is high relative to other 
measures and reflects differentiation in resilience among 
diverse populations, showing that higher levels of resil-
ience are consistent with lower levels of perceived stress 
vulnerability.60 The CD-RISC has been shown to differen-
tiate between individuals who function well after adversity 
from those who do not and measures the core features 
of resilience and the ability to tolerate experiences.69 It 
is believed that increased resilience may reduce rates of 
mental ill health.70
Well-being will be assessed using the 5-item WHO-5.57 58 
Raw scores range from 0 to 25 where 0 indicates the worst 
possible quality of life while a score of 25 represents the 
best possible quality of life. A score ≤13 or an answer of 0 or 
1 on any of the five items shows poor well-being. WHO-5 is 
a psychometrically sound measure of well-being with high 
internal consistency (Cronbach’s α=0.84) and convergent 
associations with other measures of well-being.71
Work performance will be measured using three items 
(performance items A10, A11, A12) from the HPQ61 and 
two additional items pertaining to past month sickness 
absence (days absent, days absent for MH reasons) and 
past 6-month week-long sickness absence (weeks absent, 
weeks absent for MH reasons).
Service use and management items comprised seven 
items assessing lifetime and past month service use, along 
with current medication use. Participants were also asked 
about their abilities (perceived capability and effective-
ness) to manage their mental fitness, and autonomy 
(choice and freedom) in management. These were 
scored on a 7-point Likert scale from strongly disagree to 
strongly agree.
Diagnostic interview
All those scoring 14 and above and a 10% random sample 
of those scoring below 14 on the PHQ-9 at 3-month 
follow-up will be contacted via telephone. Registered 
psychologists, trained in the use of the diagnostic instru-
ment and blinded to randomisation, will then conduct a 
telephone-based diagnostic interview using the ‘current’ 
depression section of the Mini-International Neuropsy-
chiatric Interview (MINI).72 The MINI has shown to be 
reliable and valid in eliciting symptom criteria used in the 
Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, Text Revision (DSM-IV-R) and Interna-
tional Statistical Classification of Diseases and Related 
Health Problems 10th Revision (ICD-10). The scale also 
has good concordance with the Composite International 
Diagnostic Interview with specificity ranges of 0.72–0.97 
for non-psychotic disorders in psychiatric and non-psychi-
atric populations.72
safety protocol
In any trial concerned with MH, there is the potential 
for psychological distress in participants. Although this 
study is not targeting unwell populations, based on prev-
alence data, it is predicted that 4.5% will score above 14 
on the PHQ-9 (or meet diagnosis using the instrument 
algorithm) at follow-up.73 As this unwell group may have 
more motivation to participate, we might conservatively 
predict this to be higher (15%). Those falling into this 
category (or reporting suicidal ideation) either within the 
app or at follow-up will trigger the user to be directed 
to a ‘get support’ page (at each assessment point) and 
will suggest the participant seek further help from these 
support services or their GP. Additionally, an optional 
call-back service for individuals requiring further support 
or direction is provided. This callback will occur within 
4 days from a member of staff with training in MH care 
(psychologist) and will guide participants into necessary 
care arrangements. If the team member still has concerns 
for the participant’s safety, an accredited psychiatrist will 
make contact with the participant as soon as possible. 
These participants will also receive an Short Messaging 
Service (SMS) with a range of support service contacts 
with reiteration of the advice to consult with their GP 
regarding their MH.
study hypotheses and outcomes
We hypothesise that participants receiving the headgear 
intervention will have lower levels of depression symp-
tomatology at postintervention and 3-month follow-up, 
compared with participants in the attention-matched 
control condition. While the primary analyses will 
be conducted on the entire sample (to examine the 
universal intervention effect), we also predict the inter-
vention effect to vary according to risk level (based on the 
risk calculator) and level of depression symptoms at base-
line.74 As such, analyses will be conducted to compare the 
relative effectiveness of the headgear intervention based 
on participants’ level of risk and depression symptoms at 
baseline.
Second, it is hypothesised that relative to control, 
headgear participants will have lower rates of depres-
sive disorder as detected by the PHQ algorithm and the 
two-stage diagnostic process outlined above. The inter-
vention group is also hypothesised to have improved 
anxiety symptomatology, well-being, resilience and work 
performance at postintervention and follow-up relative to 
controls.
Primary outcome
The primary outcome will be the level of depressive symp-
tomatology (as measured by the PHQ-9 sum score). The 
study primary endpoint will be the 3-month follow-up.
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Secondary outcomes
A range of secondary outcomes will be considered 
including change in anxiety symptoms (as measured by 
the GAD-2) at both 5-week and 3-month follow-up. Simi-
larly, incident cases of depression at 5-week and 3-month 
follow-up (as measured by diagnostic interview and the 
PHQ-9 diagnostic algorithm) and a reduction in the esti-
mated risk of depression (as measured by the depression 
risk algorithm) at 3-month follow-up are also secondary 
outcomes. Finally, change in Well-being (as measured by 
the WHO-5), resilience (CD-RISC 10), service use, self-de-
termination (4-item scale mentioned above) and occupa-
tional functioning (as measured by the HPQ and sickness 
absence questions) at both 5-week and 3-month follow-up 
will be outcomes of interest.
statistical analysis
Analysis plan
The composition of our sample will be demonstrated via 
simple descriptive statistics of participants’ age, gender, 
job role, industry group and baseline MH measures. 
Random imbalances between the intervention and 
control group will be examined for using χ2 tests. Primary 
analyses will be undertaken on an intent-to-treat basis, 
including all participants as randomised, regardless of 
treatment received or withdrawal from the study, with 
analysis considering recruitment strategy. Mixed-model 
repeated measures (MMRM) models will be used to 
analyse change in the primary outcome measure (PHQ-
9). The model used to test the primary hypothesis will 
only include intervention allocation and occasion of 
measurement as ‘predictors’ in the MMRM analysis of 
variance. Mathematical transformation or categorisation 
of raw scores will be undertaken to meet distributional 
assumptions and address any violation of assumptions 
required in MMRM models. When transformations have 
been undertaken to better meet distribution assumptions, 
models using the transformed data will be considered the 
main test of the primary hypotheses. MMRM uses all avail-
able data and does not involve any substitution of missing 
values with supposed or estimated values. The assump-
tions underlying MMRM allow ‘missingness’ to be related 
to observed variables in the analysis but not to unob-
served values (termed ‘missing at random’). An a priori 
planned comparison of change from baseline across the 
3-month follow-up period will be used to test the primary 
hypothesis. An unstructured variance-covariance matrix 
will be used to accommodate relationships between 
observations at different occasions. Variables found to be 
substantially imbalanced between groups postrandomi-
sation will be included in sensitivity analysis to explore 
the robustness of any findings to any chance imbalance. 
Similar analyses of scaled secondary measures will assess 
differential change due to intervention arm. For dichot-
omous outcomes such as caseness, a comparable gener-
alised mixed modelling approach will be used. Relative 
and reduction in risk of depression based on PHQ-9 score 
status and MINI interviews will be estimated at the trial 
endpoint and follow-up. Number needed to treat will be 
derived from these values. All analyses will use two-sided 
tests, with an alpha value set at 0.05.
Baseline characteristics will be used to define subgroups 
that would be the targeted if the apps were offered as a 
selective or indicated prevention. Group membership 
will be used models to evaluate moderation of effective-
ness by adding appropriate interaction terms and under-
taking planned comparisons. The effect on outcome of 
level of baseline depressive symptom levels, recruitment 
method and risk of depression calculated at baseline will 
be explored using an analysis of covariance approach 
using baseline measures as a covariate and including a 
covariate by intervention arm interaction term in models. 
The effectiveness of the active intervention at clinically 
relevant levels of baseline covariates will be assessed using 
planning comparisons while the lowest values of covari-
ates associated with a significant benefit of the interven-
tion will be established using a Johnson and Neyman75 
approach.
Sample size
As a universal prevention intervention, the size of the 
effect of the intervention is anticipated to be relatively 
small. Meta-analysis of previous trials of workplace 
prevention of depression showed a small effect size of 
d=0.17.76 Similarly, unsupported internet-based treat-
ment of depression has been shown to have a small 
effect size of d=0.25,77 consistent with the findings from 
a meta-analysis published more recently.78 Power calcula-
tions were carried out using the R package simR, which 
can undertake power calculations for mixed models 
such as those proposed to use in this study using simu-
lation techniques.79 Power was set at 80%, alpha at 0.05, 
with a two-sided hypothesis test and an assumption of 
correlation at 0.50 between preintervention and postin-
tervention scores. This estimated a sample size of 1134 
is required to detect an effect size of d=0.20 on the total 
PHQ-9 scale score at 3-month follow-up. It is predicted 
that 10% of the population will score above the exclusion 
PHQ-9 cut-off at baseline,73 increasing the initial sample 
required by 126. Finally, using a conservative attrition rate 
of 40%, an initial total sample of 2100 will need to be 
recruited and randomised.
Dissemination
We anticipate the study will be completed by 1 December 
2017. Results of this study will be disseminated for publica-
tion in peer-reviewed journals and key findings presented 
at national and international conferences.
dIsCussIon
This study will be the first randomised controlled trial to 
examine the effectiveness of a MH smartphone app in 
preventing common mental disorders. It will also be the 
largest MH prevention trial to ever be undertaken in a 
workplace setting. Given the rising cost of mental illness 
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to employers across the developed world,2 the fact that 
workplaces are one of the dominant settings in the lives 
of most individuals, and the increasing awareness of the 
role work and workplaces can play in the development of 
mental illness,80 the movement of prevention MH inter-
ventions into the workplace is arguably long overdue.
This study will provide valuable evidence regarding 
the utility of mHealth tools as a prevention method. 
Such applications provide a way to deliver interventions 
across a wide population due to flexibility and porta-
bility, increased user retention, tracking and monitoring 
features, and personalised feedback and support.26 81 
However, little is known of their utility for prevention. 
The size and design of this study will also allow for the 
direct comparing of effects of a single intervention at 
universal, selective and indicated levels of risk. This is a 
unique aspect of the study.
To date, much of the research examining prevention 
interventions for depression have focused on CBT-based 
techniques. Recent evidence suggests mindfulness-based 
interventions may have particular utility in work-
place-based eHealth interventions.32 Similarly, in recent 
years there has been renewed interest in behavioural 
treatment approaches for mental disorders, particularly 
for depression39 82 and growing evidence of the effec-
tiveness of such interventions18 and some interest in 
adapting these techniques for use with mHealth technol-
ogies.83 There is also recent work suggesting individuals 
working in some traditionally undersampled professions 
may prefer behavioural techniques over other thera-
peutic techniques that focus on cognitions or emotions.49 
Other studies have suggested men may prefer more direc-
tive approaches to psychological therapy84 and therapy 
models that emphasise action,85 which again would be in 
keeping with behavioural activity and mindfulness-based 
techniques. Given these findings, direct testing of these 
types of techniques, particularly among men, is urgently 
needed.
There are, however, some limitations in the proposed 
trial. First, since the intervention is unguided and deliv-
ered via a smartphone application, trial attrition and 
disengagement are potential issues.86 87 Reasons for attri-
tion are complex and in reality, there are contradictory 
possibilities of drop-out due to dissatisfaction or lack 
of engagement, as opposed to drop-out due to a sense 
that the individual feels their needs have been met.88 
Ultimately, use of a conservative attrition rate and statis-
tical methods robust to data missing at random, it is 
hoped this limitation will be minimised. A related issue 
is the expected challenges of collecting follow-up data 
within the required time frame. It is expected that many 
participants will be delayed in returning their 3-month 
follow-up data. As noted above, we have allowed a rela-
tively wide window for follow-up timing (90 days), which 
should help increase follow-up numbers but which at the 
cost of making it harder to interpret the impact of treat-
ment over set time periods. As with any controlled trial, 
the possibility of contamination exists, where participants 
randomised to different conditions but working in the 
same firm may exchange information. However, given the 
substantial sizes of the organisations involved, the stigma 
associated with MH and the fact the smartphone applica-
tion is specifically designed to allow participants to work 
though modules alone, it is anticipated that this occur-
rence is unlikely. Another limitation related to the use 
of a smartphone application is the potential that techno-
logical issues, such as reduced network coverage in some 
areas, and a rapidly changing market may create barriers, 
particularly among certain industries.
Participants will be recruited through industry partners 
on a volunteer basis. This will inevitably create a sample 
that is not necessarily generalisable to the whole working 
population, however, this will be somewhat ameliorated 
through social media recruitment targeting people who 
are employed. While the application is designed with 
specific working populations from MDIs as its target, the 
content of the application should have a general rele-
vance to any working individual. Additionally, voluntary 
self-selection makes the concept of universal prevention 
more contentious. Due to the opt-in nature of research 
trials and the structure of MH prevention programmes 
themselves, this is an issue faced by all trials of this nature 
and is likely to reflect the reality of such programmes 
outside of a research setting. Another potential issue 
relates to testing the effectiveness of headgear as an indi-
cated prevention tool. To do this, participants scoring 
in the diagnostic ‘grey zone’89 on the PHQ-9 will be 
included. This will be done to ensure that people with 
subsyndromal depression are included in the trial, as they 
would be in a ‘real-world’ roll-out of any prevention initia-
tive. It is acknowledged, however, that this approach may 
result in some cases of mild depression being misclassi-
fied as subsyndromal, resulting in a potential conflating 
of the concepts of prevention and very early treatment.
In attempting to increase the app’s anonymity (due to 
MH stigma) and removal of barriers, no diagnostic inter-
view will occur at baseline, as such initial diagnosis will 
not be verified. The research team felt this was a neces-
sary trade-off with respect to the case detection while 
also concurrently allowing for large numbers of partici-
pants to be recruited economically with regard to time 
and resources.90–92 Using the dual methods of excluding 
those both scoring above 14 (sensitivity=68%, speci-
ficity=95%55 93) and meeting the algorithm’s criteria, we 
believe we can be confident the baseline sample will be 
free of any significant depressive illness. The two-phase 
design94 for follow-up interviews will allow us to then 
examine incident cases of depression as a secondary 
outcome.
Overall, outcomes of the headgear trial capacity to 
empower individuals and thereby dramatically enhance 
the way working adults manage their MH and well-being. 
By using evidence-based mHealth technologies, many 
of the feasibility, access and help-seeking obstacles often 
encountered with more traditional face-to-face interven-
tions in this area can be overcome, allowing for maximal 
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reach and population impact via prevention of common 
mental disorders.
Acknowledgements The authors would like to acknowledge and thank all the 
study participants who have helped shape the content of the intervention.
Contributors  MD had a primary role in conceptualisation, write up and editing 
of this manuscript. DAJ had a role in conceptualisation, write up and editing of 
this manuscript. NG had a role in conceptualisation and editing of this manuscript. 
DM had a role in technical development and editing of this manuscript. IC had a 
role in conceptualisation, write up and editing of this manuscript. AM had a role 
in statistical conceptualisation and editing of this manuscript. AM had a role in 
conceptualisation and editing of this manuscript. RAC had a role in write up and 
editing of this manuscript. AG had a role in write up and editing of this manuscript. 
RB had a role in write up and editing of this manuscript. HC had a role in write up 
and editing of this manuscript. SBH (Senior author) had a role in conceptualisation, 
write up and editing of this manuscript. All authors read and approved of the final 
manuscript. 
Funding This study was developed in partnership with beyondblue with donations 
from the Movember Foundation. RAC is funded by an Australian Research Council 
Future Fellowship FT140100824. SBH and MD are supported by funding from the 
iCare Foundation and NSW Health.
disclaimer This paper summarises independent research and the views expressed 
herein are those of the authors.
Competing interests All authors declared that this is a beyondblue-funded study. 
All researchers have remained independent from the funders in the completion and 
submission of this work. MD, DAJ, IC, NG, DM, RAC and SBH were involved in the 
development of the headgear application. The IP is jointly owned by MD, IC, NG, DM, 
RAC and SBH, however, the authors do not currently receive any financial gain from 
this IP.
Patient consent Not required.
Ethics approval  The trial has received ethics approval from the University of New 
South Wales Human Research Ethics Committee (HC17021). 
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See:©http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years 
(DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a 
systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2012;380:2197–223.
 2. Harvey SB, Henderson M, Lelliott P, et al. Mental health and 
employment: much work still to be done. Br J Psychiatry 
2009;194:201–3.
 3. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, 
severity, and unmet need for treatment of mental disorders in the 
World Health Organization World Mental Health Surveys. JAMA 
2004;291:2581–90.
 4. Somers JM, Goldner EM, Waraich P, et al. Prevalence and incidence 
studies of anxiety disorders: a systematic review of the literature. 
Can J Psychiatry 2006;51:100–13.
 5. Waraich P, Goldner EM, Somers JM, et al. Prevalence and incidence 
studies of mood disorders: a systematic review of the literature. Can 
J Psychiatry 2004;49:124–38.
 6. Andrews G, Issakidis C, Sanderson K, et al. Utilising survey data 
to inform public policy: comparison of the cost-effectiveness of 
treatment of ten mental disorders. Br J Psychiatry 2004;184:526–33.
 7. Hickie IB. Preventing depression: a challenge for the Australian 
community. Med J Aust 2002;177 Suppl:S85–6.
 8. Berkels H, et al. Mental health promotion and prevention strategies 
for coping with anxiety, depression and stress related disorders in 
Europe. Dortmund: European Commission, 2004.
 9. Cuijpers P, Van Straten A, Smit F. Preventing the incidence of new 
cases of mental disorders: a meta-analytic review. J Nerv Ment Dis 
2005;193:119–25.
 10. Solomon D, Proudfoot J, Clarke J, et al. e-CBT (myCompass), 
Antidepressant Medication, and Face-to-Face Psychological 
Treatment for Depression in Australia: A Cost-Effectiveness 
Comparison. J Med Internet Res 2015;17:e255.
 11. Barrett PM, Farrell LJ, Ollendick TH, et al. Long-term outcomes of 
an Australian universal prevention trial of anxiety and depression 
symptoms in children and youth: an evaluation of the friends 
program. J Clin Child Adolesc Psychol 2006;35:403–11.
 12. Stice E, Shaw H, Bohon C, et al. A meta-analytic review of 
depression prevention programs for children and adolescents: 
factors that predict magnitude of intervention effects. J Consult Clin 
Psychol 2009;77:486–503.
 13. Gladstone TR, Beardslee WR. The prevention of depression 
in children and adolescents: a review. Can J Psychiatry 
2009;54:212–21.
 14. Cuijpers P, Smit F, van Straten A. Psychological treatments of 
subthreshold depression: a meta-analytic review. Acta Psychiatr 
Scand 2007;115:434–41.
 15. Rasing SP, Creemers DH, Janssens JM, et al. Effectiveness of 
depression and anxiety prevention in adolescents with high familial 
risk: study protocol for a randomized controlled trial. BMC Psychiatry 
2013;13:316.
 16. Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of 
depression recurrence in diabetes mellitus: a randomized, double-
blind, placebo-controlled trial. Arch Gen Psychiatry 2006;63:521–9.
 17. Deady M, Choi I, Calvo RA, et al. eHealth interventions for the 
prevention of depression and anxiety in the general population: 
a systematic review and meta-analysis. BMC Psychiatry 
2017;17:310.
 18. Richards DA, Ekers D, McMillan D, et al. Cost and Outcome of 
Behavioural Activation versus Cognitive Behavioural Therapy for 
Depression (COBRA): a randomised, controlled, non-inferiority trial. 
Lancet 2016;388:871–80.
 19. Tan L, Wang MJ, Modini M, et al. Preventing the development of 
depression at work: a systematic review and meta-analysis of 
universal interventions in the workplace. BMC Med 2014;12:74.
 20. Casey L, Liang R. Stress and Wellbeing in Australia Survey. AP. 
Society 2014.
 21. Battams S, Roche AM, Fischer JA, et al. Workplace risk factors for 
anxiety and depression in male-dominated industries: a systematic 
review. Health Psychol Behav Med 2014;2:983–1008.
 22. Roche AM, et al. Workplace mental illness and substance use 
disorders in male-dominated industries: A Systematic Literature 
Review: National Centre for Education and Training on Addiction 
(NCETA), 2012.
 23. Linzer M, Spitzer R, Kroenke K, et al. Gender, quality of life, and 
mental disorders in primary care: results from the PRIME-MD 1000 
study. Am J Med 1996;101:526–33.
 24. Andrews G, Issakidis C, Carter G. Shortfall in mental health service 
utilisation. Br J Psychiatry 2001;179:417–25.
 25. Proudfoot J, Clarke J, Birch MR, et al. Impact of a mobile phone 
and web program on symptom and functional outcomes for people 
with mild-to-moderate depression, anxiety and stress: a randomised 
controlled trial. BMC Psychiatry 2013;13:312.
 26. Donker T, Petrie K, Proudfoot J, et al. Smartphones for smarter 
delivery of mental health programs: a systematic review. J Med 
Internet Res 2013;15:e247.
 27. Christensen H, Griffiths KM, Jorm AF. Delivering interventions for 
depression by using the internet: randomised controlled trial. BMJ 
2004;328:265.
 28. Cockayne NL, Glozier N, Naismith SL, et al. Internet-based treatment 
for older adults with depression and co-morbid cardiovascular 
disease: protocol for a randomised, double-blind, placebo controlled 
trial. BMC Psychiatry 2011;11:10.
 29. Glozier N, Christensen H, Naismith S, et al. Internet-delivered 
cognitive behavioural therapy for adults with mild to moderate 
depression and high cardiovascular disease risks: a randomised 
attention-controlled trial. PLoS One 2013;8:e59139.
 30. Price M, Yuen EK, Goetter EM, et al. mHealth: a mechanism to 
deliver more accessible, more effective mental health care. Clin 
Psychol Psychother 2014;21:427–36.
 31. Cunningham JA, Gulliver A, Farrer L, et al. Internet interventions for 
mental health and addictions: current findings and future directions. 
Curr Psychiatry Rep 2014;16:521.
 32. Stratton E, Lampit A, Choi I, et al. Effectiveness of eHealth 
interventions for reducing mental health conditions in 
employees: A systematic review and meta-analysis. PLoS One 
2017;12:e0189904.
 33. World Medical Association. World Medical Association Declaration 
of Helsinki: ethical principles for medical research involving human 
subjects. JAMA 2013;310:2191–4.
 o
n
 17 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020510 on 13 July 2018. Downloaded from 
10 Deady M, et al. BMJ Open 2018;8:e020510. doi:10.1136/bmjopen-2017-020510
Open access 
 34. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: 
defining standard protocol items for clinical trials. Ann Intern Med 
2013;158:200–7.
 35. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised 
recommendations for improving the quality of reports of parallel-
group randomised trials. The Lancet 2001;357:1191–4.
 36. Australian Bureau of Statistics, Australian and New Zealand standard 
industrial classification. Canberra: Australian Bureau of Statistics, 
2008.
 37. Choi I, Milne DN, Glozier N, et al. Using different Facebook 
advertisements to recruit men for an online mental health study: 
Engagement and selection bias. Internet Interv 2017;8:27–34.
 38. Hopko DR, Lejuez CW, Ruggiero KJ, et al. Contemporary behavioral 
activation treatments for depression: procedures, principles, and 
progress. Clin Psychol Rev 2003;23:699–717.
 39. Lejuez CW, Hopko DR, Acierno R, et al. Ten year revision of the brief 
behavioral activation treatment for depression: revised treatment 
manual. Behav Modif 2011;35:111–61.
 40. Wood AM, Joseph S. The absence of positive psychological 
(eudemonic) well-being as a risk factor for depression: a ten year 
cohort study. J Affect Disord 2010;122:213–7.
 41. Mazzucchelli T, Kane R, Rees C. Behavioral Activation Treatments 
for Depression in Adults: A Meta-analysis and Review. Clinical 
Psychology: Science and Practice 2009;16:383–411.
 42. Walpola R. What the Buddha taught. 1967: Revised edition. Bedford: 
Gordon Fraser Gallery,, 1967.
 43. Hofmann SG, Sawyer AT, Witt AA, et al. The effect of mindfulness-
based therapy on anxiety and depression: A meta-analytic review. J 
Consult Clin Psychol 2010;78:169–83.
 44. Wang J. Work stress as a risk factor for major depressive episode(s). 
Psychol Med 1999;35:865–71.
 45. Chiesa A, Serretti A. Mindfulness-based stress reduction for stress 
management in healthy people: a review and meta-analysis. J Altern 
Complement Med 2009;15:593–600.
 46. Jacobson NS, Martell CR, Dimidjian S. Behavioral Activation 
Treatment for Depression: Returning to Contextual Roots. Clinical 
Psychology: Science and Practice 2001;8:255–70.
 47. Cribb G, Moulds ML, Carter S. Rumination and Experiential 
Avoidance in Depression. Behaviour Change 2006;23:165–76.
 48. Garnefski N, Teerds J, Kraaij V, et al. Cognitive emotion regulation 
strategies and depressive symptoms: differences between males and 
females. Pers Individ Dif 2004;36:267–76.
 49. Deady M, Peters D, Lang H, et al. Designing smartphone mental 
health applications for emergency service workers. Occup Med 
2017;67:425–8.
 50. Fernandez A, et al.. Development and validation of a prediction 
algorithm for the onset of common mental disorders in a working 
population. Australian & New Zealand Journal of Psychiatry 
2017112.
 51. Peters D, Deady M, Glozier N, et al. Worker Preferences for a Mental 
Health App Within Male-Dominated Industries: Participatory Study. 
JMIR Ment Health 2018;5:e30.
 52. Titov N, Dear BF, Johnston L, et al. Improving adherence and 
clinical outcomes in self-guided internet treatment for anxiety and 
depression: randomised controlled trial. PLoS One 2013;8:e62873.
 53. Matthews M, et al. Jo L, Designing mobile applications to support 
mental health interventions, in Handbook of Research on User 
Interface Design and Evaluation for Mobile Technology: IGI, 
Information Science Reference2008:635–56.
 54. Bakker D, Kazantzis N, Rickwood D, et al. Mental Health Smartphone 
Apps: Review and Evidence-Based Recommendations for Future 
Developments. JMIR Ment Health 2016;3:e7.
 55. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9 - Validity of a brief 
depression severity measure. Journal of General Internal Medicine 
2001;16:606–13.
 56. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med 
2001;16:606–13.
 57. Bech P. Measuring the dimensions of psychological general well-
being by the WHO-5. QoL Newsletter 2004;32:15–16.
 58. Bech P, Gudex C, Johansen S, Staehr Johansen K. The WHO (Ten) 
Weil-Being Index: Validation in Diabetes. Psychother Psychosom 
1996;65:183–90.
 59. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in 
primary care: prevalence, impairment, comorbidity, and detection. 
Ann Intern Med 2007;146:317–25.
 60. Connor KM, Davidson JR. Development of a new resilience scale: 
the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety 
2003;18:76–82.
 61. Kessler RC, Barber C, Beck A, et al. The World Health Organization 
Health and Work Performance Questionnaire (HPQ). J Occup Environ 
Med 2003;45:156–74.
 62. Andrews D, Nonnecke B, Preece J. Electronic Survey Methodology: 
A Case Study in Reaching Hard-to-Involve Internet Users. Int J Hum 
Comput Interact 2003;16:185–210.
 63. Spitzer RL, et al. Validation and utility of a self-report version of 
PRIME-MD - The PHQ primary care study. Jama-Journal of the 
American Medical Association 1999;282:1737–44.
 64. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-
report version of PRIME-MD: the PHQ primary care study. Primary 
Care Evaluation of Mental Disorders. Patient Health Questionnaire. 
JAMA 1999;282:1737–44.
 65. Martin A, Rief W, Klaiberg A, et al. Validity of the Brief Patient Health 
Questionnaire Mood Scale (PHQ-9) in the general population. Gen 
Hosp Psychiatry 2006;28:71–7.
 66. Kocalevent RD, Hinz A, Brähler E. Standardization of the depression 
screener patient health questionnaire (PHQ-9) in the general 
population. Gen Hosp Psychiatry 2013;35:551–5.
 67. Kroenke K, Spitzer RL. The PHQ-9: A New Depression Diagnostic 
and Severity Measure. Psychiatr Ann 2002;32:509–15.
 68. Löwe B, Wahl I, Rose M, et al. A 4-item measure of depression 
and anxiety: validation and standardization of the Patient Health 
Questionnaire-4 (PHQ-4) in the general population. J Affect Disord 
2010;122:86–95.
 69. Campbell-Sills L, Stein MB. Psychometric analysis and refinement 
of the Connor-davidson Resilience Scale (CD-RISC): Validation of a 
10-item measure of resilience. J Trauma Stress 2007;20:1019–28.
 70. Southwick SM, Vythilingam M, Charney DS. The psychobiology of 
depression and resilience to stress: implications for prevention and 
treatment. Annu Rev Clin Psychol 2005;1:255–91.
 71. Krieger T, Zimmermann J, Huffziger S, et al. Measuring depression 
with a well-being index: further evidence for the validity of the 
WHO Well-Being Index (WHO-5) as a measure of the severity of 
depression. J Affect Disord 2014;156:240–4.
 72. Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International 
Neuropsychiatric Interview (MINI). A short diagnostic structured 
interview: reliability and validity according to the CIDI. European 
Psychiatry 1997;12:224–31.
 73. Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure 
of current depression in the general population. J Affect Disord 
2009;114(1-3):163–73.
 74. Imamura K, Kawakami N, Furukawa TA, et al. Effects of an Internet-
based cognitive behavioral therapy (iCBT) program in Manga format on 
improving subthreshold depressive symptoms among healthy workers: 
a randomized controlled trial. PLoS One 2014;9:e97167. ArtID e97167.
 75. Johnson PO, Neyman J. Tests of certain linear hypotheses and their 
application to some educational problems. Statistical Research 
Memoires 1936;1:57–93.
 76. Tan L, Wang M-J, Modini M, et al. Erratum to: preventing the 
development of depression at work: a systematic review and meta-
analysis of universal interventions in the workplace. BMC Med 
2014;12:212.
 77. Andersson G, Cuijpers P. Internet-Based and Other Computerized 
Psychological Treatments for Adult Depression: A Meta-Analysis. 
Cogn Behav Ther 2009;38:196–205.
 78. Cuijpers P, Donker T, Johansson R, et al. Self-guided psychological 
treatment for depressive symptoms: a meta-analysis. PLoS One 
2011;6:e21274.
 79. Green P, MacLeod CJ. SIMR: an R package for power analysis of 
generalized linear mixed models by simulation. Methods Ecol Evol 
2016;7:493–8.
 80. Harvey SB, Modini M, Joyce S, et al. Can work make you 
mentally ill? A systematic meta-review of work-related risk 
factors for common mental health problems. Occup Environ Med 
2017;74:301–10.
 81. Harrison V, Proudfoot J, Wee PP, et al. Mobile mental health: review 
of the emerging field and proof of concept study. J Ment Health 
2011;20:509–24.
 82. Martell C.R., Dimidjian S, et al; Behavioral Activation for Depression: 
A Clinician's Guide: The Guilford Press, 2013.
 83. Ly KH, Topooco N, Cederlund H, et al. Smartphone-Supported 
versus Full Behavioural Activation for Depression: A Randomised 
Controlled Trial. PLoS One 2015;10:e0126559.
 84. Rochlen AB, O'Brien KM. The relation of male gender role 
conflict and attitudes toward career counseling to interest in and 
preferences for different career counseling styles. Psychol Men Masc 
2002;3:9–21.
 85. Atkinson DR, Worthington RL, Dana DM, et al. Etiology beliefs, 
preferences for counseling orientations, and counseling 
effectiveness. J Couns Psychol 1991;38:258–64.
 86. Leykin Y, Muñoz RF, Contreras O, et al. Results from a trial of an 
unsupported internet intervention for depressive symptoms. Internet 
Interv 2014;1:175–81.
 o
n
 17 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020510 on 13 July 2018. Downloaded from 
11Deady M, et al. BMJ Open 2018;8:e020510. doi:10.1136/bmjopen-2017-020510
Open access
 87. Donker T, Bennett K, Bennett A, et al. Internet-delivered interpersonal 
psychotherapy versus internet-delivered cognitive behavioral 
therapy for adults with depressive symptoms: randomized controlled 
noninferiority trial. J Med Internet Res 2013;15:e82.
 88. Christensen H, Griffiths K, Groves C, et al. Free range users and one hit 
wonders: community users of an Internet-based cognitive behaviour 
therapy program. Aust N Z J Psychiatry 2006;40:59–62.
 89. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief 
depression severity measure. J Gen Intern Med 2001;16:606–13.
 90. Newman SC, Shrout PE, Bland RC. The efficiency of two-phase 
designs in prevalence surveys of mental disorders. Psychol Med 
1990;20:183–93.
 91. Van Hooff M, McFarlane AC, Davies CE, et al. The Australian Defence 
Force Mental Health Prevalence and Wellbeing Study: design and 
methods. Eur J Psychotraumatol 2014;5:23950. epub.
 92. Burdett H, Fear NT, Jones N, et al. Use of a two-phase process to 
identify possible cases of mental ill health in the UK military. Int J 
Methods Psychiatr Res 2016;25:168–77.
 93. Manea L, Gilbody S, McMillan D. Optimal cut-off score for 
diagnosing depression with the Patient Health Questionnaire (PHQ-
9): a meta-analysis. CMAJ 2012;184:E191–E196.
 94. Pickles A, Dunn G, Vázquez-Barquero JL. Screening for stratification 
in two-phase ('two-stage') epidemiological surveys. Stat Methods 
Med Res 1995;4:73–89.
 o
n
 17 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020510 on 13 July 2018. Downloaded from 
